Xiamen C&D Life Sciences Co., Ltd. (C&D Life Sciences) was officially inaugurated on September 20. Initiated by C&D Group and jointly funded by C&D Healthcare and C&D Emerging Industry Equity Investment, the new company marks an important step in the Group’s efforts to cultivate new growth drivers and expand into life sciences.

Life sciences have become a strategic frontier in global technological competition and industrial transformation. Aligned with Xiamen’s “421” Plan for Core Industry Expansion and Upgrading, C&D Group is actively helping to develop three priority sectors: New Energy & Advanced Materials, Biomedicine, and Artificial Intelligence. The establishment of C&D Life Sciences responds to the city’s strategic priorities and strengthens the Group’s role in industrial investment and operations. It also positions the Group to capitalize on opportunities in the growing bioeconomy and gain a competitive edge in developing new quality productive forces.

As a new platform for growth, C&D Life Sciences will drive industrial investment and operations across the broader healthcare sector. It will help C&D Group cultivate new growth drivers while supporting the development of Xiamen’s biomedicine industry.